Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531189 · ClinicalTrials.gov registry record
Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease
A clinical trial, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 16
- Enrollment target
NCT04531189 is a clinical trial that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 16 participants.
The verdict
NCT04531189 has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future clinical studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-11 |
| Est. Completion | 2022-03-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04531189
The ClinicalTrials.gov registry entry for NCT04531189 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04531189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04531189 about?
NCT04531189 is a clinical study titled "Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease". The primary objective of the study is to determine the relevance and appropriateness of outcome assessments, including biomarkers, within the Wilson disease population to inform study design and endpoint selection for future clinical studies.
What is the current status of trial NCT04531189?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2020-12-11. Estimated completion is 2022-03-25.
Who is sponsoring clinical trial NCT04531189?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.